• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn
 
  • Détails
Titre

Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Archives of Disease in Childhood. Fetal and Neonatal Edition  
Auteur(s)
Tolsa, J. F.
Auteure/Auteur
Cotting, J.
Auteure/Auteur
Sekarski, N.
Auteure/Auteur
Payot, M.
Auteure/Auteur
Micheli, J. L.
Auteure/Auteur
Calame, A.
Auteure/Auteur
Liens vers les personnes
Sekarski-hunkeler, Nicole  
Cotting, Jacques  
Tolsa, Jean-François  
Liens vers les unités
Pédiatrie  
Néonatologie  
ISSN
1359-2998
Statut éditorial
Publié
Date de publication
1995-05
Volume
72
Numéro
3
Première page
F184
Dernière page/numéro d’article
7
Notes
Clinical Trial
Journal Article --- Old month value: May
Résumé
Eleven newborns admitted consecutively to the neonatal unit with respiratory failure and severe persistent pulmonary hypertension (PPHN) were included in a clinical trial to assess the efficacy of magnesium sulphate (MgSO4) in the treatment of PPHN. A loading dose of 200 mg/kg MgSO4 was given over 20 minutes, followed by a continuous infusion of 20-150 mg/kg/hour to obtain a magnesium blood concentration between 3.5 and 5.5 mmol/l. Mean (SD) duration of treatment was 75.5 (19.8) hours. No other vasodilatory drug was administered before or during the treatment and patients were not hyperventilated. Mean (SEM) PaO2 values significantly increased from 42.6 (8.8) before treatment to 70.3 (24.1) mm Hg after 24 hours, with no change in pH or PCO2. Oxygen index and alveolar-arterial oxygen gradient (A-aDO2) were significantly lower after 24 hours; respectively, 46.8 (15.2) to 28.0 (9.0) and 624.3 (11.3) to 590 (58) mm Hg. Mean airway pressure could be significantly reduced from 19.5 (3.1) to 13.9 (3.9) cm H2O after 72 hours. Mean ventilatory time support was 131 hours and mean total oxygen dependency 10 days. No systemic hypotension nor any other adverse effect were noted. All infants survived and the neurodevelopmental assessment was normal at 6 and 12 months of age. It is concluded that magnesium sulphate is a non-aggressive and low-cost treatment of short duration which is easy to apply. It may have a role in the various treatment of PPHN.
Sujets

Drug Administration S...

PID Serval
serval:BIB_59FFBA924E97
DOI
10.1136/fn.72.3.F184
PMID
7796235
WOS
A1995QZ45700009
Permalien
https://iris.unil.ch/handle/iris/69454
Open Access
Oui
Date de création
2008-01-25T09:28:32.376Z
Date de création dans IRIS
2025-05-20T16:12:26Z
  • Copyright © 2024 UNIL
  • Informations légales